Hainan Huluwa Pharmaceutical Group (605199.SH) has obtained the registration certificate for calcitriol soft capsules.

Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the company recently received the "Drug Registration Certificate" for Alfacalcidol Soft Capsules issued by the National Medical Products Administration (referred to as the "NMPA"). It is reported that the indications for Alfacalcidol Soft Capsules include: 1. Postmenopausal osteoporosis; 2. Chronic renal failure, especially renal osteodystrophy in patients undergoing hemodialysis; 3. Hypoparathyroidism post-surgery; 4. Idiopathic hypoparathyroidism; 5. Pseudohypoparathyroidism; 6. Vitamin D-dependent rickets; 7. Hypophosphatemic vitamin D-resistant rickets, etc. The drug was evaluated and approved based on the technical requirements consistent with the quality and efficacy of the reference drug, and its approval is equivalent to passing the evaluation of generic drug quality and efficacy consistency.